Younes R, Govaere O, Petta S, Miele L, Tiniakos D, Burt A, et al
instabile Produktverfgbarkeit
These requirements mirror those that may have limited adoption of Rybelsus, the oral semaglutide from Novo Nordisk approved for diabetes in 2019. One challenge in developing oral versions of semaglutide is that the drug is based on chains of amino acids known as peptides which are subject to degradation by enzymes in the stomach. In contrast, Eli Lillys upcoming oral GLP1 candidate, orforglipron, is a smallmolecule drug rather than a peptide, which could lessen the need for dosing requirements and offer greater convenience to users. This ease of use has fueled expectations of growing market share for oral GLP-1 formulations, with analysts estimating they could generate $22 billion annually by 2030, capturing 24% of the global weight loss market. For plan sponsors, the arrival of oral options means usage could grow, reinforcing the need for comprehensive utilization-management strategies
Taking it with a small meal can help
Less than a week later, Roche announced positive topline results from two arms of an ongoing, multi-part, phase I clinical trial for CT-996, an investigational, once-daily, oral GLP-1 receptor agonist being developed for the treatment of both Type 2 diabetes and obesity
